Analyst Sees This Kidney Disease Company’s Stock Could Rise Sixfold, But Lists Two Issues

Piper Sandler raised its price target on Ardelyx Inc (NASDAQ: ARDX) to $8 from $3 and upgraded to Overweight from a Neutral rating. The upgrade follows a surprisingly positive advisory committee vote ...

Ardelyx stock rockets on heavy volume after positive FDA panel vote on kidney disease treatment

Shares of Ardelyx Inc. ARDX, +35.66% rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. Food and Drug Administration voted that be...

New York State Boldly Moves To Reduce Deaths From Kidney Disease

While the nation is convulsed by another gun shooting and activists demand new gun laws to address the epidemic, it’s worth noting that more people will die this year of an affliction that is mu...